Arcellx Inc ACLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACLX is a good fit for your portfolio.
News
-
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
-
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
-
Arcellx Provides First Quarter 2024 Financial Results
-
Arcellx to Participate in Two Upcoming Investor Conferences
-
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
Arcellx Shares Rise Premarket on Expanded Gilead Collaboration
-
Gilead Invests Further in Arcellx, Extends Collaboration
Trading Information
- Previous Close Price
- $54.15
- Day Range
- $53.43–54.35
- 52-Week Range
- $30.78–75.03
- Bid/Ask
- $54.15 / $54.32
- Market Cap
- $2.91 Bil
- Volume/Avg
- 70,916 / 463,847
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 130
- Website
- https://www.arcellx.com
Comparables
Valuation
|
Metric
|
ACLX
|
CGEM
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.81 | 2.33 | 0.68 |
Price/Sales | 20.37 | — | — |
Price/Cash Flow | 399.26 | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACLX
|
CGEM
|
VOR
|
|---|---|---|---|
Quick Ratio | 5.32 | 19.75 | 8.13 |
Current Ratio | 5.46 | 20.33 | 8.46 |
Interest Coverage | −22.10 | — | — |
Quick Ratio
ACLX
CGEM
VOR
Profitability
|
Metric
|
ACLX
|
CGEM
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −1.99% | −21.39% | −48.29% |
Return on Equity (Normalized) | −3.75% | −22.60% | −61.06% |
Return on Invested Capital (Normalized) | −7.24% | −26.73% | −54.20% |
Return on Assets
ACLX
CGEM
VOR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bwhkvyz | Ggrly | $124.7 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ccgyshmq | Rbtjx | $110.4 Bil | |||
| Moderna Inc
MRNA
| Syrdqbfvk | Hhsf | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Qlkkzpq | Jnt | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Ncylvnb | Qpjg | $22.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xdcygrnzt | Gwtpy | $19.4 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qtzzttwy | Yznttng | $15.3 Bil | |||
| Incyte Corp
INCY
| Sgjrzqnd | Fffwm | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sjdxxwgjjn | Vzshg | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Zfsfztwr | Sklsz | $12.2 Bil |